KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Short term Debt (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Short term Debt for 16 consecutive years, with $29.1 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 119.29% to $29.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Dec 2025, up 119.29% year-over-year, with the annual reading at $29.1 million for FY2025, 119.29% up from the prior year.
  • Short term Debt hit $29.1 million in Q4 2025 for Inovio Pharmaceuticals, down from $50.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $50.4 million in Q3 2025 to a low of $491645.0 in Q3 2021.
  • Historically, Short term Debt has averaged $10.4 million across 5 years, with a median of $1.8 million in 2021.
  • Biggest five-year swings in Short term Debt: crashed 38.15% in 2021 and later skyrocketed 1148.11% in 2023.
  • Year by year, Short term Debt stood at $548032.0 in 2021, then surged by 198.12% to $1.6 million in 2022, then skyrocketed by 909.21% to $16.5 million in 2023, then dropped by 19.61% to $13.3 million in 2024, then skyrocketed by 119.29% to $29.1 million in 2025.
  • Business Quant data shows Short term Debt for INO at $29.1 million in Q4 2025, $50.4 million in Q3 2025, and $11.4 million in Q2 2025.